Revelation Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Revelation Biosciences has a total shareholder equity of $2.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.7M and $4.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.54m |
| Equity | US$2.67m |
| Total liabilities | US$4.07m |
| Total assets | US$6.74m |
Recent financial health updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28Financial Position Analysis
Short Term Liabilities: REVB's short term assets ($6.7M) exceed its short term liabilities ($4.1M).
Long Term Liabilities: REVB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: REVB is debt free.
Reducing Debt: REVB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REVB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: REVB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.6% each year